Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.
Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.
Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, Taipei, Taiwan
Northwestern University, Chicago, Illinois, United States
Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
Loma Linda University Health, Loma Linda, California, United States
Seoul National University Hospital, Seoul, Korea, Republic of
Ålesund Hospital Trust, Ålesund, Norway
Nordlandssykehuset Bodø, Bodø, Norway
Stavanger University Hospital, Stavanger, Norway
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Malmö university, Malmö, Sweden
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
David Vyles, Milwaukee, Wisconsin, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.